D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications. In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.
तुलना करने के लिए मीट्रिक्स | 347850 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध347850पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −105.1x | −16.8x | −0.5x | |
PEG अनुपात | −4.18 | −0.13 | 0.00 | |
क़ीमत/बुक | 48.5x | 3.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 436.8x | 21.4x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 21.6% | 44.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | −6.1% | 4.9% | अनलॉक करें |